Mitchell M D, Miller D M
Cornell University, Ithaca, NY, USA.
Drugs Today (Barc). 2012 Aug;48(8):519-24. doi: 10.1358/dot.2012.48.8.1848664.
Vitreomacular traction (VMT) syndrome and macular hole (MH) are disease processes that are caused by anomalous separation of the vitreous from the macula. Until now, management of these conditions has involved vitreoretinal surgery. Clinical trials have shown that a single intravitreal microplasmin (ocriplasmin) injection can induce separation of the vitreous from the macular surface and thereby relieve the tractional changes that contribute to vision loss from VMT and MH. Herein, we summarize the results of these trials which demonstrate that a significant number of intravitreal ocriplasmin-treated patients have resolution of their vitreoretinal interface abnormalities without the need for vitreoretinal surgery.
玻璃体黄斑牵拉（VMT）综合征和黄斑裂孔（MH）是由玻璃体与黄斑异常分离引起的疾病过程。到目前为止，这些病症的治疗一直涉及玻璃体视网膜手术。临床试验表明，单次玻璃体内注射微纤溶酶（ocriplasmin）可诱导玻璃体与黄斑表面分离，从而缓解导致VMT和MH视力丧失的牵拉性改变。在此，我们总结了这些试验的结果，这些结果表明，大量接受玻璃体内ocriplasmin治疗的患者无需进行玻璃体视网膜手术即可解决其玻璃体视网膜界面异常问题。
